Keller Rohrback L.L.P. Announces Investigation of Pfizer Smoking Cessation Drug Chantix

SEATTLE--(BUSINESS WIRE)-- Attorney Advertising. Keller Rohrback L.L.P. (www.krclassaction.com) announces that it is investigating Pfizer, Inc. (NYSE: PFE) regarding the smoking cessation pill Chantix. There are reports that some Chantix users have committed or attempted suicide, had psychotic episodes, suffered from depression, or suffered from other serious problems as a result of using this drug. This information was reportedly left out of the crucial safety review of Chantix due to Pfizer allegedly submitting data regarding the drug through “improper channels.”

If you or someone you know may have been injured as a result of using Chantix, or you would like more information regarding our investigation, please contact attorney Michael Woerner at 800.776.6044 or via email at [email protected].

Keller Rohrback, with offices in Seattle, Phoenix, New York, and Santa Barbara, has successfully represented hundreds of clients injured by prescription drugs such as Fen-Phen, Baycol, and Vioxx. Our Complex Litigation Group is proud to offer its expertise in personal injury cases to clients nationwide.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.



CONTACT:

Keller Rohrback L.L.P.
Michael Woerner, Attorney
800-776-6044
[email protected]
www.krclassaction.com

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Mental Health  Pharmaceutical  Professional Services  Legal

MEDIA:

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.